Adaptive Radiotherapy
13
9
10
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
8%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (13)
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow
the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer
Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors
Adaptive Radiotherapy in Head and Neck Tumor Patients
Adaptive Radiotherapy in Patients With Gynecological Tumors